HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients

doi:10.1016/0731-7085(94)E0027-X

Journal of Pharmaceutical and Biomedical Analysis

Volume 12, Issue 7, July 1994, Pages 923-930

https://doi.org/10.1016/0731-7085(94)E0027-X Get rights and content

Abstract

Sensitive and selective high performance liquid chromatographic (HPLC) methods for the quantification of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)₃] and glucuronide metabolite (CP94-GLUC) in urine and serum of thalassaemic patients are described. Three separate analyses are involved. The first assay quantifies both CP94 and its iron complex. This procedure requires the conversion of the iron complex to the free ligand and is carried out using diethylenetriaminepentaacetic acid (DTPA). CP94 and the internal standard, 1-propyl-2-ethyl-3-hydroxypyridin-4-one (CP95) present in either serum or urine are then extracted at pH 7.0 with dichloromethane. Extraction efficiency is 96.0 ± 5.6% and 100 ± 7.1% for CP94 and CP95, respectively, and 31.2 ± 2.1% at 30 μM and 53.2 ± 4.2% at 300 μM for the corresponding iron complex. In the second assay, samples are incubated (16 h) with β-glucuronidase and processed as before. In this assay, the drug, its iron complex and glucuronide conjugate are measured. In the third assay the iron complex of CP94, [Fe(III) (CP94)₃] is quantified. From the three separate analyses it is possible to calculate the individual concentrations of the three separate components present in serum and urine of thalassaemic patients. Calibration for both components, i.e. CP94 (assays 1 and 2) and its iron complex (assay 3) are linear with correlation coefficients >0.99 and are reproducible over the required concentration range of 0–500 μM for the free ligand and 0–100 μM for the iron complex. The minimum quantifiable level is 0.5 μM for the free ligand and 1.0 μM for the iron complex.

References (10)

J.B. Porter et al.
Blood
(1988)
R.O. Epemolu et al.
J. Chromatogr.
(1990)
S. Singh et al.
Anal. Biochem.
(1990)
R.O. Epemolu et al.
J. Chromatogr. Biomed. Applic.
(1992)
B. Halliwell et al.
Biochem. J.
(1984)

There are more references available in the full text version of this article.

Cited by (12)

Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug
2019, Photodiagnosis and Photodynamic Therapy
Citation Excerpt :
It should be noted that efficacy would have been much improved if normal lesion pre-treatment had been conducted but it was decided not to do this in these initial clinical studies, so that histological measurements could be employed as endpoints. CP94 [57] and its close relation relation, CP20 (1,2-dimethyl-3-hydroxypyridin-4-one; L1; Deferiprone; DFP) have also been investigated as iron chelating agents in humans not undergoing PDT, with the latter being studied in detail in long term investigations of daily oral administration [58,59]. There is rapid first pass metabolism by the liver following oral administration of CP20 in humans [60] which limits the clinical effectiveness of these particular hydroxypyridinone iron chelators for the treatment of conditions of iron overload [61,62], resulting in Deferasirox administration being utilised, either on its own or in combination with the established Deferoxamine long infusion treatment regime [63].
Photodynamic therapy (PDT) is a light activated drug therapy that can be used to treat a number of cancers and precancers. It is particularly useful in its topical form in dermatology but improvement of efficacy is required to widen its application.
An ester between aminolaevulinic acid (ALA) and CP94 was synthesised (AP2-18) and experimentally evaluated to determine whether protoporphyrin IX (PpIX)-induced PDT effectiveness could be improved. A biological evaluation of AP2-18 was conducted in cultured human primary cells with both PpIX fluorescence and cell viability (as determined via the neutral red assay) being assessed in comparison to the PpIX prodrugs normally utilised in clinical practice (aminolaevulinic acid (ALA) or its methyl ester (MAL)) either administered alone or with the comparator iron chelator, CP94.
No significant dark toxicity was observed in human lung fibroblasts but AP2-18 significantly increased PpIX accumulation above and beyond that achieved with ALA or MAL administration +/- CP94 in both human dermal fibroblasts and epithelial squamous carcinoma cells. On light exposure, the combined hydroxypyridinone iron chelating ALA prodrug AP2-18 generated significantly greater cytotoxicity than any of the other treatment parameters investigated when the lowest concentration (250 μM) was employed.
Newly synthesised AP2-18 is therefore concluded to be an efficacious prodrug for PpIX-induced PDT in these dermatologically relevant human cells, achieving enhanced effects at lower concentrations than currently possible with existing pharmaceuticals.
Porous graphitic carbon: A versatile stationary phase for liquid chromatography
2010, Journal of Chromatography A
Iron
2004, Comprehensive Coordination Chemistry II
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator
2004, Biochemical Pharmacology
Citation Excerpt :
As shown in Fig. 8, pretreatment with iron or zinc completely blocked cleavage of both the intitiator caspase 9 as well as the executioner caspase 3. Although the distribution of biometals complexed by synthetic chelating agents is of great importance to their biological effects, there are relatively few reports of attempts to identify intra- and extracellular metal complexes resulting from chelator treatment [29,30]. To our knowledge, complexes of tachpyr have not been previously studied.
Tachpyridine (N,N′,N″-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane; tachpyr) is a potent hexadentate iron chelator under preclinical investigation as a potential anti-cancer agent. Tachpyridine induces apoptosis in cultured cancer cells by triggering a mitochondrial pathway of cell death that is p53-independent. To explore the relationship between the chelation chemistry of tachpyridine and its biological activity, a sensitive and specific reversed-phase high-performance liquid chromatography (RP-HPLC) method was devised and used to measure tachpyr and its metal complexes in cells and tissue culture media. Major species identified in cells treated with tachpyr were tachpyr itself, [Zn(tachpyr)]²⁺, and iron coordinated to two partially oxidized species of tachpyridine, [Fe(tachpyr-ox-2)]²⁺, and [Fe(tachpyr-ox-4)]²⁺. The kinetics of intracellular accumulation of [Zn(tachpyr)]²⁺ and [Fe(tachpyr-ox-2)]²⁺ were markedly different: [Zn(tachpyr)]²⁺ rapidly reached plateau levels, whereas intracellular levels of [Fe(tachpyr-ox-2)]²⁺ and free tachpyr rose steadily. At the last timepoint measured, 9% of total cellular iron and 13% of total cellular zinc were bound by tachpyridine. Taken together, [Zn(tachpyr)]²⁺, [Fe(tachpyr-ox-2)]²⁺, and free tachpyr accounted for virtually all of the tachpyr added, indicating that iron and zinc are the principal metals targeted by tachpyridine in cells. Consistent with these findings, activation of the apoptotic caspases 9 and 3 was blocked in cells pre-treated with either iron or zinc. Pretreatment with either of these metals also completely protected cells from the cytotoxic effects of tachpyridine. These results demonstrate a link between metal depletion and chelator cytotoxicity, and suggest that intracellular chelation of zinc as well as iron may play a role in the cytotoxicity of tachpyridine.
Recent applications of high-performance liquid chromatography to the analysis of metal complexes
1997, Journal of Chromatography A
Interest in metal complexes in modern inorganic chemistry has resulted in increasing demands for the analysis of these compounds. This paper reviews the most recent applications of high-performance liquid chromatography (HPLC) to the analysis of metal complexes. The review centres on the use of the technique in metal complex syntheses, reactions, characterizations and complexations and retention behaviour of these compounds, as reported in the literature since 1994.
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs
2023, International Journal of Molecular Sciences

View all citing articles on Scopus

View full text

HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients

Abstract

Blood

J. Chromatogr.

Anal. Biochem.

J. Chromatogr. Biomed. Applic.

Biochem. J.

HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)₃] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients